Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions

  • Authors:
    • Giuliana Gobbi
    • Prisco Mirandola
    • Cristina Micheloni
    • Elvira Solenghi
    • Ivonne Sponzilli
    • Marco Artico
    • Giuseppe Soda
    • Giuliana Zanelli
    • Giuseppe Pelusi
    • Tania Fiorini
    • Lucio Cocco
    • Marco Vitale
  • View Affiliations

  • Published online on: December 1, 2004     https://doi.org/10.3892/ijo.25.6.1625
  • Pages: 1625-1629
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Malignant transformation of breast epithelia is frequently associated with an altered expression of MHC products and of antigen processing molecular machinery. The consequent impairment of tumor immune recognition is thought to confer to tumor cells a selective advantage with respect to survival and metastatization. In order to understand if metastatic breast cancer lesions might be associated with a defective proteasome subunit expression that, in turn, might limit the peptide availability and prevent stable cell surface HLA class I-tumor antigen expression, we studied by immunostaining the expression of β2-microglobulin, HLA class I antigens and proteasome subunits LMP-2 and LMP-10 in 35 matched primary and metastatic human breast carcinoma lesions. Overall, we found a downregulation of LMP-2 in 51.4= of the lesions, of LPM-10 in 45.7= of the lesions, of HLA class I heavy chain in 40.0= of the lesions, while β2-microglobulin was downregulated in 25.7= of the lesions studied. In most primary and metastatic lesions the downmodulation of each antigen examined was coordinated. In the cases where a selective downmodulation of antigens was observed in the primary or in the metastatic lesion (with the exception of β2-microglobulin), it was rather observed in the primary lesions. However, LMP-10 showed a significant selective downmodulation in the metastases as well. Antigen downmodulation does not appear therefore to represent a strategy for the primary tumor to metastasize successfully.

Related Articles

Journal Cover

December 2004
Volume 25 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Gobbi G, Mirandola P, Micheloni C, Solenghi E, Sponzilli I, Artico M, Soda G, Zanelli G, Pelusi G, Fiorini T, Fiorini T, et al: Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions. Int J Oncol 25: 1625-1629, 2004
APA
Gobbi, G., Mirandola, P., Micheloni, C., Solenghi, E., Sponzilli, I., Artico, M. ... Vitale, M. (2004). Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions. International Journal of Oncology, 25, 1625-1629. https://doi.org/10.3892/ijo.25.6.1625
MLA
Gobbi, G., Mirandola, P., Micheloni, C., Solenghi, E., Sponzilli, I., Artico, M., Soda, G., Zanelli, G., Pelusi, G., Fiorini, T., Cocco, L., Vitale, M."Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions". International Journal of Oncology 25.6 (2004): 1625-1629.
Chicago
Gobbi, G., Mirandola, P., Micheloni, C., Solenghi, E., Sponzilli, I., Artico, M., Soda, G., Zanelli, G., Pelusi, G., Fiorini, T., Cocco, L., Vitale, M."Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions". International Journal of Oncology 25, no. 6 (2004): 1625-1629. https://doi.org/10.3892/ijo.25.6.1625